Two nerve block methods for pain after open abdominal blood vessel surgery
Compares a single numbing injection with a catheter for pain after vascular surgery.
Key facts
- Who runs it
- Hartford Hospital
- Where
- Hartford, United StatesSee the site
- Trial code
- Registry title
- Liposomal Bupivacaine/Bupivacaine in Rectus Sheath Blocks Versus Ropivacaine in Rectus Sheath Blocks And Catheters
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 14 people, planned
- Started
- 18 Oct 2023
- Expected to end
- 30 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Liposomal bupivacaine
- Ropivacaine
- Bupivacain
- Record updated
- 3 September 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults having planned open vascular surgery through a cut in the middle of the belly. It compares two ways of numbing the belly wall for pain relief after surgery.
- Age
- 18 to 80 years
- Sex
- All sexes
- Disease stage
- Planned (not emergency) vascular surgery with an open mid-belly cut, such as abdominal aortic aneurysm repair, mesenteric artery bypass, or aortobifemoral bypass for aortic blockage. ASA physical status score I-IV. People already in hospital without vascular symptoms can join if surgery is at least three days after admission. Must speak and read English.
- Earlier treatment
- Cannot join if taking long-acting opioids, or using more than 50 MME of opioids per day for at least 30 days within 90 days before surgery.
Main reasons for not taking part
- Emergency surgery, or hospital stay due to symptoms like severe belly pain or a burst aneurysm
- Allergy to local numbing drugs, or a reason the belly-wall nerve block cannot be done
- Weight under 40 kg (88 lb)
- Chronic pain syndrome seen recently by the pain service, or cancer spread to distant organs confirmed by CT scan
- Current drug or heavy alcohol use, or within the last 3 months; or planned extra belly-wall surgery
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Patients aged 18-80 years
- Patients scheduled for elective vascular surgery with an open mid-abdominal laparotomy incision, including abdominal aortic aneurysm repair surgery (AAA), mesenteric artery bypass surgery, and aortobifemoral bypass surgery for aortic occlusive disease
- Patients who are able to speak and read English
- Patients with American Society of Anesthesiology (ASA) physical status score I-IV
- Patients who are admitted to the hospital and are incidentally discovered to require any of the aforementioned surgeries, being asymptomatic for vascular issues, and having their surgery scheduled no sooner than three days after admission, are also considered eligible
Who cannot take part
- Patients with contraindications to RSB, including but not limited to anatomical abnormality, previous surgical intervention that limits or prevents receiving bilateral RSBs, or infection at the injection site
- Patients who take long-acting opioid medication, or on continuous opioid use > 50 MME per day for at least 30 days within 90 days prior to surgery
- Patients who are unable to receive postoperative ropivacaine intermittent boluses within the first 5 days after surgery due to issues with their catheter (such as dislodgement, migration, or kinking) will be excluded from the final analysis
- Patients with a plan to undergo abdominal wall surgery, in addition to the vascular surgery that involves a mid-abdomen incision, such as abdominal wall reconstruction surgery. The additional abdominal wall incisions or interventions might have an impact on the study's pain, opioid, and LOS outcomes
- Emergency vascular reconstruction surgery., patients admitted to the hospital due to symptoms directly associated with their vascular condition, such as severe abdominal pain or a ruptured aneurysm causing bleeding, will be excluded
- History of allergy to local anesthetics
- Patients who have chronic pain syndrome with a recent preoperative consultation with the chronic pain service. Also, patients with distant metastatic cancers (e.g. bone, lung, brain) confirmed by CT scan
- Patients with current substance abuse, or history of substance abuse within 3 months, this includes any illicit drugs (not including marijuana) or excessive alcohol consumption as defined as 4 or more drinks per day or 8 or more drinks per week for women and 5 or more drinks per day or 15 or more drinks per week for men
- Weight < 40 kg, as a combination of 20 mL of Bupivacaine 0.25% with 30 mL of LB is greater than the maximal dose allowed, given concern for local anesthetic toxicity
- Lack or refusal to sign the study consent
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
This trial is currently available in United States.
- Hartford HospitalHartford, United StatesContact: Kevin J Finkel, MDTaking people
About the trial
What the trial wants to find out
The goal of this pilot study is to compare single shot rectus sheath blocks of liposomal bupivacaine/bupivacaine mixture to bilateral rectus sheath catheters infused with ropivacaine (standard of care at our facility) in patients undergoing vascular surgery with an open mid-abdominal laparotomy incision. This study will assess the safety and feasibility of this approach compared to standard of care.
Read full original descriptionShow less
Participants will receive either a single dose of liposomal bupivacaine/bupivacaine mixture intraoperatively at the end of surgery through bilateral rectus sheath blocks (LB/B group) or the standard of care ropivacaine intraoperatively at the end of surgery through bilateral rectus sheath blocks with the insertion of bilateral RS catheter for continuous ropivacaine infusion plus repeated daily boluses (Catheter group; standard care). They will be assessed for differences in the rate of postoperative complications, resources consumed with each intervention, as well as postoperative pain scores, opioid consumption, hospital and PACU length of stay, patient's satisfaction, and quality of recovery, and hospital length of stay.
The 2 groups in the trial
- RSB LB/BTreatment being tested
Rectus Sheath Block: Total 60mL: (20mL 1.3% LB + 30mL 0.25% bupivacaine + 10mL NS) (30mL per side)
Treatment: Liposomal bupivacaine and Bupivacain
- RSB/RSC RopivacaineExisting treatment, for comparison
Rectus Sheath Block: Total 60mL of 0.2% ropivacaine (3 vials) (30mL per side) \+ Rectus Sheath Catheter intermittent hourly boluses of 0.2% ropivacaine 10mL/hr per side
Treatment: Ropivacaine
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Liposomal Bupivacaine/Bupivacaine A Single-Dose Bilateral Rectus Sheath Blocks Versus Ropivacaine in Bilateral Rectus Sheath Blocks And Catheters With Intermittent Hourly Boluses.
- Plain-language title
- Two nerve block methods for pain after open abdominal blood vessel surgeryGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Criteria questions
- Built from NCT05972018, who can take part
- Record updated
- 3 September 2025